Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
Type:
Grant
Filed:
March 13, 2017
Date of Patent:
October 2, 2018
Assignee:
AbbVie Inc.
Inventors:
Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
Abstract: The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.
Abstract: The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-PD-L1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.
Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Type:
Grant
Filed:
January 19, 2018
Date of Patent:
September 18, 2018
Inventors:
Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.
Type:
Grant
Filed:
October 11, 2016
Date of Patent:
September 11, 2018
Assignees:
Duke University, The United States of America as Represented by the Secretary Department of Health and Human Services (NIH)
Inventors:
Darell D. Bigner, Chien-Tsun Kuan, Ira H. Pastan, Charles Pegram
Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
September 11, 2018
Assignee:
HOFFMANN-LA ROCHE INC.
Inventors:
Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Guy Georges, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
Abstract: The present invention provides isolated antibodies that bind to 14-3-3 epsilon that are useful in the recognition of tumor cells and tumor specific delivery of drugs and therapies.
Abstract: Methods are provided for enhancing immunization strategies by manipulation, e.g. in vitro manipulation, of phagocytic antigen presenting cells. In the methods of the invention, phagocytic antigen presenting cells (phAPC) are incubated with a particulate antigen in the presence of an anti-CD47 agent in a dose and for a period of time sufficient to allow the phAPC to phagocytose the particulate antigen, which process generates a “loaded” phAPC. The loaded phAPC is contacted with a population of T cells matched for at least one major histocompatibility locus with the phAPC, where the T cells are stimulated after contacting to generate an effector response against an epitope or epitopes present on the particulate antigen.
Type:
Grant
Filed:
April 23, 2014
Date of Patent:
September 4, 2018
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Diane Tseng, Jens-Peter Volkmer, Kipp Andrew Weiskopf, Stephen Willingham, Irving L. Weissman
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
Type:
Grant
Filed:
January 23, 2018
Date of Patent:
August 7, 2018
Assignee:
PFIZER INC.
Inventors:
Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
Abstract: There is disclosed compositions and methods relating to or derived from anti-CD47 antibodies. More specifically, there is disclosed fully human antibodies that bind CD47, CD47-antibody binding fragments and derivatives of such antibodies, and CD47-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
Type:
Grant
Filed:
March 4, 2016
Date of Patent:
July 31, 2018
Assignee:
SORRENTO THERAPEUTICS, INC.
Inventors:
Barbara A. Swanson, John Dixon Gray, Heyue Zhou
Abstract: Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.
Abstract: The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
Abstract: The present disclosure relates to a method of treating cancer using a composition including a target-specific self-illuminative nanocomplex which includes a self-illuminative nanocomplex including a quantum dot and a modified self-illuminative protein (m-Rluc8), a targeted cancer-specific molecule and a hydrophilic polymer, and a method of preparing the composition. Since the high efficiency self-illuminative nanocomplex may have high target specificity by chemically binding to a target-specific molecule, it can be effectively used in cancer treatment using a nanometer-scale laser light source, and therefore it is expected to propose a new paradigm of nanoptic therapeutics.
Type:
Grant
Filed:
April 16, 2015
Date of Patent:
July 3, 2018
Assignee:
Research & Business Foundation Sungkyunkwan University
Abstract: The present invention relates to compositions comprising polypeptides, especially polypeptides capable of specifically binding predetermined antigens. The polypeptide in the composition comprises at least two antigen binding sites. These at least two antigen binding sites are located on a single polypeptide chain. One of the at least two antigen binding sites specifically binds the human CD3 antigen. The polypeptide may exist in both monomeric form and multimeric form. The multimeric form of the polypeptide constitutes no more than 5% of the total weight of the combined monomeric and multimeric forms of said polypeptide.
Type:
Grant
Filed:
November 26, 2004
Date of Patent:
June 19, 2018
Assignee:
AMGEN RESEARCH (MUNICH) GMBH
Inventors:
Robert Hofmeister, Nadja Prang, Andreas Wolf, Frank Hanakam, Thomas Urbig, Christian Itin, Patrick Baeuerle
Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
June 19, 2018
Assignee:
Immunomedics, Inc.
Inventors:
Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.
Type:
Grant
Filed:
March 1, 2016
Date of Patent:
May 29, 2018
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Samuel Davis, Eric Smith, Douglas MacDonald, Kara Louise Olson
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
Type:
Grant
Filed:
March 30, 2016
Date of Patent:
May 15, 2018
Assignee:
PFIZER INC.
Inventors:
Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal
Abstract: Monoclonal antibodies against LRP6 and that block the Wnt signaling pathway are disclosed. Methods of production and use thereof are also disclosed.
Type:
Grant
Filed:
April 4, 2016
Date of Patent:
May 15, 2018
Assignee:
The Board of Regents of the University of Oklahoma
Abstract: Disclosed are antibodies (immunoglobulins) and fragments thereof that hydrolyze or bind polypeptide antigens belonging to Staphyloccus aureus, hepatitis C virus, human immunodeficiency virus and Alzheimer's disease. Also disclosed are novel methods to improve the antigen reactivity of the immunoglobulins and to treat a pathophysiological condition using the immunoglobulins as therapeutics.
Type:
Grant
Filed:
October 23, 2009
Date of Patent:
May 15, 2018
Assignee:
Covalent Bioscience Incorporated
Inventors:
Sudhir Paul, Stephanie Planque, Yasuhiro Nishiyama, Eric L. Brown, Keri C. Smith, Hiroaki Taguchi
Abstract: The present disclosure relates to a nucleotide sequence comprising the sequence of SEQ ID NO: 5, and/or sequence of SEQ ID NO: 6, vector and host cell line comprising the nucleotide. The present disclosure also relates to an antibody that binds to extracellular region of human CD147, wherein the antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2, and/or a light chain variable region having the amino acid sequence of SEQ ID NO: 1, and the antibody contains a glycoform lacking both fucose residues and xylose residues, pharmaceutical composition comprising the antibody or fragment thereof, the method of producing the antibody or fragment thereof, and use of the pharmaceutical composition in treatment of CD147 expression-related diseases.
Type:
Grant
Filed:
October 7, 2015
Date of Patent:
May 8, 2018
Assignee:
FOURTH MILITARY MEDICAL UNIVERSITY
Inventors:
Zhinan Chen, Zheng Zhang, Yang Zhang, Fei Feng, Muren Huhe, Xiangmin Yang